DexTech Medical AB (XSAT:DEX) Other Long-Term Liabilities: kr0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:DEX DexTech Medical AB XSAT:DEX
23 GF Score
Price kr10.40
! 3 Warning Signs
View Full Analysis

What is DexTech Medical AB Other Long-Term Liabilities?

DexTech Medical AB XSAT:DEX +0.48% 23 Other Long-Term Liabilities is kr0.00 Mil as of Mar. 2026. GuruFocus rates XSAT:DEX with a GF Score™ of 23/100. The stock has 3 warning signs investors should review.

DexTech Medical AB's other long-term liabilities for the quarter that ended in Mar. 2026 was kr0.00 Mil.

DexTech Medical AB's quarterly other long-term liabilities increased from Sep. 2025 (kr-0.85 Mil) to Dec. 2025 (kr0.00 Mil) but then stayed the same from Dec. 2025 (kr0.00 Mil) to Mar. 2026 (kr0.00 Mil).

DexTech Medical AB Other Long-Term Liabilities Related Terms

DexTech Medical AB Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for DexTech Medical AB's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexTech Medical AB Other Long-Term Liabilities Chart

DexTech Medical AB Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DexTech Medical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.85 0.00 0.00
XSAT:DEX
23GF Score
DexTech Medical AB XSAT:DEX
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexTech Medical AB Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of kr0.00 Mil mean?
DexTech Medical AB (XSAT:DEX) has a Other Long-Term Liabilities of kr0.00 Mil as of Mar. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on DexTech Medical AB and its competitors.
Is DexTech Medical AB's Other Long-Term Liabilities too high?
DexTech Medical AB's current Other Long-Term Liabilities is kr0.00 Mil. Overall, DexTech Medical AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does DexTech Medical AB's Other Long-Term Liabilities compare to VRTX and REGN?
DexTech Medical AB's Other Long-Term Liabilities of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on DexTech Medical AB and its competitors. DexTech Medical AB's current Other Long-Term Liabilities is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexTech Medical AB stock overvalued right now?
DexTech Medical AB (XSAT:DEX) has a current Other Long-Term Liabilities of kr0.00 Mil. The current Other Long-Term Liabilities is kr0.00 Mil. DexTech Medical AB's overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For DexTech Medical AB (XSAT:DEX), the current Other Long-Term Liabilities is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DexTech Medical AB Business Description

Address Dag Hammarskjolds Vag 34A, Uppsala, SWE, 752 37
DexTech Medical AB is a Swedish research company specializing in drug development for urological oncology, with a prominent focus on prostate cancer. The company develops drug candidates using a proprietary carbohydrate platform, advancing treatments aimed at castration-resistant prostate cancer and related conditions. Its operations center on research, development, and licensing of these drug candidates. It has four drug candidates: OsteoDex, SomaDex, PSMA-binding conjugates, and GuaDex.
23GF Score

Get the complete analysis for XSAT:DEX

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr10.40
Price